The platinum-free combination significantly improved EFS, OS, and pathologic complete response rates compared with standard neoadjuvant gemcitabine/cisplatin.

For men with lower urinary tract symptoms (LUTS) attributable to benign prostatic hyperplasia (BPH) who are continuous users of tamsulosin, about one-third have ...

FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.

A new treatment is approved to reduce proteinuria in adults with primary immunoglobulin A nephropahty; a swimmer’s ear treatment and the thyroid hormone replacement therapy Amerithroid are now ...

Treatments for fibrodysplasia ossificans progressiva, gastroenteropancreatic neuroendocrine tumors, HIV, influenza, and multiple myeloma are under review.

The share of US adults taking GLP-1 medications to lose weight has reached a record 11%, a new Medicare program that began July 1 could drive that figure higher still.